Methods and compositions for treating or preventing cancer
This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.
1 . A method for treating or preventing a medical condition, in a subject, selected from the group consisting of neuroblastoma, rhabdomyosarcoma, osteosarcoma, pancreatic cancer, Wilm's tumor and pediatric cancer comprising administering a therapeutically effective amount of one or more IGF1R inhibitors or pharmaceutical compositions thereof to the subject.
2 . The method of claim 1 wherein the IGF1R inhibitor is selected from the group consisting of
and an isolated antibody that binds specifically to human IGF1R or an antigen-binding fragment thereof.
3 . The method of claim 2 wherein the antibody comprises:
(a) a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 2 and a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10 or 12;
(b) a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 4 and a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10 or 12;
(c) a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 6 and a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10 or 12; or
(d) a light chain variable region comprising amino acids 20-128 of SEQ ID NO: 8 and a heavy chain variable region comprising amino acids 20-137 of SEQ ID NO: 10 or 12.
4 . The method of claim 1 wherein the IGF1R inhibitor is administered in association with one or more further chemotherapeutic agents or a pharmaceutical composition thereof.
5 . The method of claim 4 wherein the further chemotherapeutic agent is one or more members selected from the group consisting of teniposide doxorubicin
any liposomal formulation thereof, cyclophosphamide
13-cis-retinoic acid
6 . The method of claim 4 wherein the IGF1R inhibitor and the further anti-cancer therapeutic agent are administered simultaneously.
7 . The method of claim 4 wherein the IGF1R inhibitor and the further anti-cancer therapeutic agent are administered non-simultaneously.
8 . The method of claim 2 wherein the antibody comprises an IgG constant region.
9 . The method of claim 1 wherein the subject is a human.
10 . The method of claim 9 wherein the subject is a child.
11 . The method of claim 1 wherein the IGF1R inhibitor is administered in association with an anti-cancer therapeutic procedure.
12 . The method of claim 11 wherein the anti-cancer therapeutic procedure is surgical tumorectomy and/or anti-cancer radiation treatment.